Loading patent…
AssigneePolium Technologies, Inc.
InventorsHamilton J. Lenox, Elena Terentieva, Mikhail Y. Gololobov
Estimating the term…
(R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: 1 wherein R1, R2, and R4 are independently selected from —H or —F, at least one of R1, R2, and R4 is —F, and R3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.
(R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine.
An anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analogs.
A method of providing vasoconstriction in a mammal, comprising the step of administering to said mammal an amount of (R)-6F-epinephrin or (R)-6F-phenylephrine effective to provide vasoconstricting activity.
A composition comprising:
A local anesthetic composition comprising:
A method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, comprising the steps of:
A method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, comprising the steps of:
PaHNL-poly-N-isopropylacrylamide (Finezyme™-H1).
PaHNL-poly(N-isopropylacrylamide-co-N-tert-butylacrylamide) (Finezyme™-H2).
PaHNL-Eudragit L-100 (Finezyme™-H3).
PaHNL-Eudragit S-100 (Finezyme™-H4).
Dependencies are inferred from the claim text.